These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 439328)

  • 1. Marijuana may lessen spasticity of MS.
    Check WA
    JAMA; 1979 Jun; 241(23):2476. PubMed ID: 439328
    [No Abstract]   [Full Text] [Related]  

  • 2. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis.
    Ungerleider JT; Andyrsiak T; Fairbanks L; Ellison GW; Myers LW
    Adv Alcohol Subst Abuse; 1987; 7(1):39-50. PubMed ID: 2831701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The use of medical-grade cannabis in patients non-responders to Nabiximols.
    Saccà F; Pane C; Carotenuto A; Massarelli M; Lanzillo R; Florio EB; Brescia Morra V
    J Neurol Sci; 2016 Sep; 368():349-51. PubMed ID: 27538663
    [No Abstract]   [Full Text] [Related]  

  • 4. Cannabis and multiple sclerosis.
    Fragoso YD; Carra A; Macias MA
    Expert Rev Neurother; 2020 Aug; 20(8):849-854. PubMed ID: 32515670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Basinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2014 Mar; 176(12A):. PubMed ID: 25350886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What's new in multiple sclerosis spasticity research? Poster session highlights.
    Linker R
    Neurodegener Dis Manag; 2017 Nov; 7(6s):51-53. PubMed ID: 29143588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What is new in multiple sclerosis spasticity research? Poster session highlights.
    Ghezzi A
    Neurodegener Dis Manag; 2016 Dec; 6(6s):45-47. PubMed ID: 27874498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral cannabinoids for spasticity in multiple sclerosis: will attitude continue to limit use?
    Metz L; Page S
    Lancet; 2003 Nov; 362(9395):1513. PubMed ID: 14615102
    [No Abstract]   [Full Text] [Related]  

  • 9. [There is evidence for the use of cannabinoids for symptomatic treatment of multiple sclerosis].
    Bazinski H; Jensen HB; Stenager E
    Ugeskr Laeger; 2015 May; 177(20):956-60. PubMed ID: 26535431
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical experience with THC:CBD oromucosal spray in patients with multiple sclerosis-related spasticity.
    Koehler J; Feneberg W; Meier M; Pöllmann W
    Int J Neurosci; 2014 Sep; 124(9):652-6. PubMed ID: 24392812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A review of the effects of baclofen and of THC:CBD oromucosal spray on spasticity-related walking impairment in multiple sclerosis.
    Arroyo González R
    Expert Rev Neurother; 2018 Oct; 18(10):785-791. PubMed ID: 30235965
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluate symptomatic therapy in MS: can clinical trials be fine-tuned?
    Solaro C
    Eur J Neurol; 2011 Sep; 18(9):1113-4. PubMed ID: 21726356
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety, tolerability, and efficacy of orally administered cannabinoids in MS.
    Russo EB
    Neurology; 2003 Feb; 60(4):729-30; author reply 729-30. PubMed ID: 12601130
    [No Abstract]   [Full Text] [Related]  

  • 14. Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.
    Podda G; Constantinescu CS
    Expert Opin Biol Ther; 2012 Nov; 12(11):1517-31. PubMed ID: 22954177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sativex in the management of multiple sclerosis-related spasticity: An overview of the last decade of clinical evaluation.
    Giacoppo S; Bramanti P; Mazzon E
    Mult Scler Relat Disord; 2017 Oct; 17():22-31. PubMed ID: 29055461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.
    Otero-Romero S; Sastre-Garriga J; Comi G; Hartung HP; Soelberg Sørensen P; Thompson AJ; Vermersch P; Gold R; Montalban X
    Mult Scler; 2016 Oct; 22(11):1386-1396. PubMed ID: 27207462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical experiences with cannabinoids in spasticity management in multiple sclerosis.
    Lorente Fernández L; Monte Boquet E; Pérez-Miralles F; Gil Gómez I; Escutia Roig M; Boscá Blasco I; Poveda Andrés JL; Casanova-Estruch B
    Neurologia; 2014 Jun; 29(5):257-60. PubMed ID: 24035293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic use of cannabis derivatives].
    Benyamina A; Reynaud M
    Rev Prat; 2014 Feb; 64(2):165-8. PubMed ID: 24701869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Palatability and oral cavity tolerability of THC:CBD oromucosal spray and possible improvement measures in multiple sclerosis patients with resistant spasticity: a pilot study.
    Lus G; Cantello R; Danni MC; Rini A; Sarchielli P; Tassinari T; Signoriello E
    Neurodegener Dis Manag; 2018 Apr; 8(2):105-113. PubMed ID: 29683408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.
    Ferrè L; Nuara A; Pavan G; Radaelli M; Moiola L; Rodegher M; Colombo B; Keller Sarmiento IJ; Martinelli V; Leocani L; Martinelli Boneschi F; Comi G; Esposito F
    Neurol Sci; 2016 Feb; 37(2):235-42. PubMed ID: 26474875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.